(Q42982910)

English

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study

scientific article published on 3 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study (English)

1 reference

Europe PubMed Central

12 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

Hertzel C. Gerstein

4

1 reference

Europe PubMed Central

12 November 2017

1

object named as

Bernard Zinman

1 reference

Europe PubMed Central

12 November 2017

Anthony J Hanley

8

object named as

Anthony J G Hanley

1 reference

Europe PubMed Central

12 November 2017

author name string

Stewart B Harris

2

1 reference

Europe PubMed Central

12 November 2017

Jan Neuman

3

1 reference

Europe PubMed Central

12 November 2017

Ravi R Retnakaran

5

1 reference

Europe PubMed Central

12 November 2017

Janet Raboud

6

1 reference

Europe PubMed Central

12 November 2017

Ying Qi

7

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

3 June 2010

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

376

1 reference

Europe PubMed Central

12 November 2017

9735

1 reference

Europe PubMed Central

12 November 2017

103-111

1 reference

Europe PubMed Central

12 November 2017

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of ramipril on the incidence of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of nateglinide on the incidence of diabetes and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining sulfonylureas and other oral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of proposed oral disposition index measures in relation to the actual disposition index

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960746-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)60746-5

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42982910&oldid=2093252676"